Discovery of 5-phenyl-3-ureidothiophene-2-carboxamides as protective agents for ALS patient iPSC-derived motor neurons.

Bioorg Med Chem Lett

Pharmaceutical Research Laboratories, Toray Industries, Inc., 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan.

Published: November 2024

We discovered novel neuroprotective compounds by phenotypic screening using SOD1-mutant amyotrophic lateral sclerosis (ALS) patient induced pluripotent stem cell (iPSC)-derived motor neurons. Mechanistic analysis showed that the protective effect of initial hit compound 1 was likely due to the inhibition of MAP4Ks, including MAP4K4, a member of the MAP4K kinase family. Structural transformation led to compound 15f, which showed improved MAP4K4 inhibitory activity and superior neuroprotective effects compared to 1 in motor neurons. The results suggest that structural optimization based on MAP4K4 inhibitory activity might improve the neuroprotective effect of this series of compounds.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2024.129935DOI Listing

Publication Analysis

Top Keywords

motor neurons
12
als patient
8
ipsc-derived motor
8
map4k4 inhibitory
8
inhibitory activity
8
discovery 5-phenyl-3-ureidothiophene-2-carboxamides
4
5-phenyl-3-ureidothiophene-2-carboxamides protective
4
protective agents
4
agents als
4
patient ipsc-derived
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!